Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension

Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study

(2019) Mitsuhiro Nishimoto et al.   HYPERTENSION RESEARCH

Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study

(2019) Sadayoshi Ito et al.   JOURNAL OF HUMAN HYPERTENSION

Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria

(2019) Sadayoshi Ito et al.   Clinical Journal of the American Society of Nephrology

Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects

(2018) Manabu Kato et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A DOUBLE BLIND PHASE III STUDY OF ESAXERENONE (CS-3150) COMPARED TO EPLERENONE IN PATIENTS WITH ESSENTIAL HYPERTENSION (ESAX-HTN STUDY)

(2018) S. Ito et al.   JOURNAL OF HYPERTENSION

Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease

(2018) Akira Nishiyama   HYPERTENSION RESEARCH

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016

(2016) Murray Epstein et al.   AMERICAN JOURNAL OF MEDICINE

Add-On Use of Eplerenone Is Effective for Lowering Home and Ambulatory Blood Pressure in Drug-Resistant Hypertension

(2016) Kazuo Eguchi et al.   Journal of Clinical Hypertension

Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium

(2016) George C. Roush et al.   JOURNAL OF HYPERTENSION

Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis

(2016) Dena Ettehad et al.   LANCET

Nonsteroidal antagonists of the mineralocorticoid receptor

(2015) Peter Kolkhof et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats

(2015) Kiyoshi Arai et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy

(2015) George L. Bakris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

(2015) Bryan Williams et al.   LANCET

Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: Systematic review and meta-analysis

(2014) Francesco Pelliccia et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury

(2014) Peter Kolkhof et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

2013 ESH/ESC Guidelines for the management of arterial hypertension

(2013)   EUROPEAN HEART JOURNAL

Nifedipine controlled-release 40 mg b.i.d. in Japanese patients with essential hypertension who responded insufficiently to nifedipine controlled-release 40 mg q.d.: a phase III, randomized, double-blind and parallel-group study

(2013) Kazuaki Shimamoto et al.   HYPERTENSION RESEARCH

Mineralocorticoid receptor antagonists: their use and differentiation in Japan

(2012) Atsuhisa Sato   HYPERTENSION RESEARCH

Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension

(2012) GianLuca Colussi et al.   JOURNAL OF HYPERTENSION

Rapid Reversal of Left Ventricular Hypertrophy and Intracardiac Volume Overload in Patients With Resistant Hypertension and Hyperaldosteronism

(2010) Krishna Gaddam et al.   HYPERTENSION

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

(2010) Faiez Zannad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Programming of Hypertension

(2009) Rebecca M. Reynolds et al.   HYPERTENSION

Plasma Aldosterone and Its Relationships With Left Ventricular Mass in Essential Hypertensive Patients With the Metabolic Syndrome

(2008) G. Mule et al.   AMERICAN JOURNAL OF HYPERTENSION

High plasma aldosterone and low renin predict blood pressure increase and hypertension in middle-aged Caucasian populations

(2008) P Meneton et al.   JOURNAL OF HUMAN HYPERTENSION

Relation of Dietary Salt and Aldosterone to Urinary Protein Excretion in Subjects With Resistant Hypertension

(2007) Eduardo Pimenta et al.   HYPERTENSION